BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27878398)

  • 21. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
    Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
    Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
    Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
    El-Mahdy HA; El-Husseiny AA; Kandil YI; Gamal El-Din AM
    Life Sci; 2020 Dec; 262():118518. PubMed ID: 33011221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
    Mayer P; Harjung A; Breinig M; Fischer L; Ehemann V; Malz M; Scherübl H; Britsch S; Werner J; Kern MA; Bläker H; Schirmacher P; Bergmann F
    Endocr Relat Cancer; 2012 Jun; 19(3):217-32. PubMed ID: 22194440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.
    Tavernier E; Flandrin-Gresta P; Solly F; Rigollet L; Cornillon J; Augeul-Meunier K; Stephan JL; Montmartin A; Viallet A; Guyotat D; Campos L
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1753-8. PubMed ID: 22706881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
    Li Y; Zhang T; Schwartz SJ; Sun D
    Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.
    Wong C; Chen S
    Cancer Res; 2009 Nov; 69(22):8670-7. PubMed ID: 19861537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
    Saturno G; Valenti M; De Haven Brandon A; Thomas GV; Eccles S; Clarke PA; Workman P
    Oncotarget; 2013 Aug; 4(8):1185-98. PubMed ID: 23852390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
    Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
    Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
    Pedersen KS; Kim GP; Foster NR; Wang-Gillam A; Erlichman C; McWilliams RR
    Invest New Drugs; 2015 Aug; 33(4):963-8. PubMed ID: 25952464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
    Hertlein E; Wagner AJ; Jones J; Lin TS; Maddocks KJ; Towns WH; Goettl VM; Zhang X; Jarjoura D; Raymond CA; West DA; Croce CM; Byrd JC; Johnson AJ
    Blood; 2010 Jul; 116(1):45-53. PubMed ID: 20351313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.
    Khaledian B; Taguchi A; Shin-Ya K; Kondo-Ida L; Kagaya N; Suzuki M; Kajino T; Yamaguchi T; Shimada Y; Takahashi T
    Cancer Sci; 2021 Mar; 112(3):1225-1234. PubMed ID: 33370472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
    Song D; Chaerkady R; Tan AC; García-García E; Nalli A; Suárez-Gauthier A; López-Ríos F; Zhang XF; Solomon A; Tong J; Read M; Fritz C; Jimeno A; Pandey A; Hidalgo M
    Mol Cancer Ther; 2008 Oct; 7(10):3275-84. PubMed ID: 18852131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
    Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
    Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer.
    Ma L; Sato F; Sato R; Matsubara T; Hirai K; Yamasaki M; Shin T; Shimada T; Nomura T; Mori K; Sumino Y; Mimata H
    Oncol Rep; 2014 Jun; 31(6):2482-92. PubMed ID: 24718854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.